Answers are grounded in this paper and cite their sources.
Oral bioavailability is a crucial pharmacokinetic parameter optimised by drug developers working on new therapeutic compounds. The goal is to obtain adequate systemic exposure and to establish safe and effective therapeutic dosages. Critical to optimising oral bioavailability is understanding a compounds susceptibility to first-pass metabolism, determined by the intricate relationship between gut absorption, metabolism, and hepatic metabolism. Efforts to model this relationship in vitro have led to the emergence of microphysiological systems (MPS) that consist of multiple, fluidically linked organs. Here we describe an MPS that links the gut and liver capable of simulating both oral and intravenous dosing routes and is made up of entirely primary human cells: a gut barrier tissue comprised of an intestinal epithelial monolayer derived from the human jejunum, and a liver microtissue, derived from primary human hepatocytes (PHH). Functionality of gut and liver tissues is maintained in co-culture enabling the pharmacokinetic investigation of oral compounds. We combine the primary Gut/Liver MPS with a mechanistic mathematical model to generate organ-specific pharmacokinetic parameters and estimate human oral bioavailability and its components: the fraction absorbed ( F a ) , the fraction escaping gut wall elimination ( F g ) , and the fraction escaping hepatic elimination ( F h ) . We use the CYP3A mediated compound midazolam, which is subject to both intestinal and hepatic extraction, to demonstrate the transformative potential of the primary Gut/Liver MPS to mechanistically model the pharmacokinetics of oral compounds in vitro .
No takes yet. Share an insight, caveat, or question.
Abbas et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: